Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03801928 · ClinicalTrials.gov registry record
Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 118
- Enrollment target
NCT03801928: Completed study, sponsored by Pfizer.
NCT03801928 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 118 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03801928 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 118 participants
- Enrollment target
Study Summary
This is a prospective, observational, multicenter study conducted in adult patients with ulcerative colitis (UC) or Crohn's disease (CD). The study plans to recruit 300 subjects in the United States and Canada in which the participating physician has decided to treat with INFLECTRA. The study will evaluate treatment patterns, adherence, disease activity, remission status, relapse status, treatment satisfaction, and healthcare resource utilization. Patient outcomes will be assessed at four time points (quarterly) for approximately 52 weeks after the decision to initiate treatment with INFLECTRA.
Interventions
- DRUG Inflectra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2018-02-23 |
| Est. Completion | 2020-02-07 |
What the finished NCT03801928 record still lists
NCT03801928 is an observational study that tracks outcomes without assigning an intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Inflectra is the first listed.
NCT03801928 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03801928 about?
NCT03801928 is a clinical study titled "Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease". This is a prospective, observational, multicenter study conducted in adult patients with ulcerative colitis (UC) or Crohn's disease (CD). The study plans to recruit 300 subjects in the United States and Canada in which the participating physician has decided to treat with INFLECTRA. The study will e...
What is the current status of trial NCT03801928?
This trial is currently completed. The enrollment target is 118 participants. The study started on 2018-02-23. Estimated completion is 2020-02-07.
What interventions are being tested in trial NCT03801928?
The interventions under investigation include: Inflectra (DRUG).
Who is sponsoring clinical trial NCT03801928?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI